High prevalence of gastroesophageal reflux disease (GERD) to foster the growth of the ranitidine market
Ranitidine, an anti-platelet drug, is the second most popular choice among diabetics to lower blood sugar. The main properties of Ranitidine are its glycoside bound trimethylester, trihalomethanes (THMs), and its suppression of platelet activity. It was first introduced in the United States in 1981 and is now available throughout the world. Ranitidine (also known as Niaspan) is most useful for treating gastric ulcers and conditions such as gastritis, cholecystitis, and duodenal ulcers caused by Helicobacter pylori infection. Ranitidine has a faster onset of action than that of metformin, a commonly prescribed ulcer drug. The growing prevalence of high prevalence of gastroesophageal reflux disease (GERD) and stomach ulcers is propelling the growth of the ranitidine market. According to the National Center for Biotechnology Information, in the United States, peptic ulcer disease affects approximately 4.6 million people annually, with an estimated 10% of the US population having evi...